To report the longer term outcomes following either a strategy of endovascular repair first or open repair of ruptured abdominal aortic aneurysm, which are necessary for both patient and clinical decision-making.
Introduction
Ruptured abdominal aortic aneurysm (AAA) is fatal in over 80% of cases and operative mortality remains high in those who survive to undergo repair (42%). 1 The majority of patients in Europe, the USA, and elsewhere is treated with open surgical repair rather than the less invasive endovascular aneurysm repair (EVAR) 1 -4 and emergency EVAR is not available, or not always available, in many centres.
Following a small pilot trial, 5 three larger European randomized trials of endovascular vs. open repair of ruptured aneurysms were established, with the aim of testing the hypothesis that 30-day outcomes were better after either endovascular repair or an endovascular strategy: observational studies suggest that operative mortality after emergency endovascular repair is in the range of 16 -36%, varying with haemodynamic stability. 3, 4 The conventional reporting standard for surgery is 30-day mortality and all three later randomized trials have reported this outcome recently. 6 -8 In the two smaller trials, which recruited a limited range of patients, who were fit for open repair and after CT scan deemed anatomically suitable for EVAR, 30-day mortality (20 -25%) was similar in patients randomized to EVAR vs. open repair. 6, 8 The much larger IMPROVE trial, randomized patients at the point of in-hospital clinical diagnosis, when vascular teams were alerted, but before a CT scan had confirmed either the diagnosis or the anatomical suitability for EVAR. Randomization was to an endovascular strategy (EVAR wherever possible, with open repair for those anatomically unsuitable for standard EVAR) vs. open repair. The aim of this trial was to assess the clinical and costeffectiveness of a preferential endovascular strategy for the management of suspected ruptured AAA. Again there was no 30-day survival benefit for the endovascular strategy, except perhaps in women, with overall mortality 35%. 7 An editorial commentary on the 30-day outcomes of the IMPROVE trial emphasized correctly that modern intensive care permitted more patients to survive to 30 days, with many patients still being in hospital at 30 days, so that only an assessment of longer term outcomes, to 90 days and beyond, would provide the requisite evidence for both clinical and patient decision-making. 9 This need for longer term data also is endorsed by a recent Cochrane review and the IDEAL recommendations. 10, 11 To the patients and their families involved in the design of the IMPROVE trial, the most important outcome was going home without major complications. Here we report the 1-year pre-specified outcomes from the IMPROVE trial. 
Methods

Randomization
The trial used central telephone computer-generated randomization (1:1) , stratified by centre with variable block size. 7 Since this was a surgical trial focusing on mortality there was no blinding.
Outcomes
The principal longer term outcome was all-cause mortality at 1 year and other 1 year measures included aneurysm-specific mortality, re-interventions, health-related quality-of-life (QoL), resource use, disposal (length of hospital stay and the patient-preferred outcome of discharge home, see Supplementary material online, 
Statistical analysis
The trial required the recruitment of 600 patients to show a 14% absolute difference in survival between the randomized groups with .90% power. Analyses were by intention-to-treat, with the principal sensitivity analysis restricted to the 502 patients with a confirmed diagnosis of rupture in whom repair was commenced, according to the prespecified analysis plan (www.improvetrial.org). The proportion surviving at 1-year post-randomization was compared between the randomized groups, using a Pearson's x 2 test without continuity correction, and odds ratios were reported using logistic regression before and after adjustment for sex, age (continuous measure), and Hardman Index 17 (continuous, a validated scoring system for ruptured AAA).
Kaplan -Meier survival curves were plotted after censoring at the end of follow-up or at 1 year, whichever came first, for overall and aneurysm-specific mortality and time to first re-intervention, using log-rank tests for between-group comparisons. As previously 7 , we fitted a complier average causal effects model to estimate the potential effect of all patients adhering to trial protocol. Gray's non-parametric test, accounting for competing risks, was used to compare the cumulative incidence of overall discharge (from index admission hospital and secondary hospital) and for discharge to home (time to discharge compared with Wilcoxon rank-sum test). For pre-specified subgroups (age, sex, and Hardman index), differences were assessed using logistic regression with a test of interaction; given the multiple tests performed an interaction test P-value of ,0.01 was required to claim strong evidence of differences between subgroups. The EQ-5D utility index score was calculated by combining the EQ-5D health profile of each patient with health state preference values from the UK general population. 14 The resultant mean QoL utility scores at 3 and 12 months postrandomization were contrasted between the randomized groups, with unpaired t-tests. Quality-Adjusted-Life-Years up to 1 year were calculated by valuing each patient's survival time by their QoL at 3 and 12 months according to the 'area under the curve' method. 18 The study estimated INBs by valuing incremental QALYs at the recommended threshold for a QALY gain (£30 000) then subtracting the incremental costs from this with conversions into E (£1:E1.235 19 ) reported (see Supplementary material online, Appendix for details). Missing data on baseline covariates (Hardman index), QoL, and resource use were addressed with multiple imputation 20 (see Supplementary material online Appendix and Table S3 ). Sensitivity analyses to explore the robustness of the results to alternative assumptions were conducted, e.g. different staffing levels for the emergency operation or varying the unit costs of the EVAR device.
Results
One-year survival data were available for 611/613 patients randomized ( Figure 1) . Of the 613 patients, 536 had proven AAA rupture, and repair was started in 502 (see Figure 1 ). For the 77 patients without AAA rupture, 22 had acute, symptomatic AAA (with repair in 21), while of the 55 patients with discharge diagnoses unrelated to AAA 45 had co-existing asymptomatic AAA (mean diameter 6.9 cm) and 1 further patient had a thoracoabdominal aneurysm. Baseline characteristics were similar between the randomized groups 7 (see Supplementary material online, Figure 2A) . At 1 year, AAA-related mortality (including all deaths within 30 days) in the endovascular strategy and open repair groups, respectively, was 33.9% and 39.3%, unadjusted odds ratio of 0.79 (95% CI 0.57, 1.10), P ¼ 0.161 (see Supplementary material online, Figure S1 ). The subgroup analysis of 1-year mortality found weak evidence that the endovascular strategy was more effective in women than in men, ratio of odds ratio 0.41 (95% CI 0.18, 0.93), P ¼ 0.034 ( Figure 2B) . Among ruptured aneurysm patients with repair One patient mortality known to 30 days and one patient mortality known to 3 months. Case record form (CRF) captures re-interventions and re-admissions, and outpatient visits to the trial hospital.
Endovascular strategy or open repair started, the 1-year mortality was 98/259 (37.8%) in the endovascular strategy group and 104/241 (43.2%) in the open repair group, adjusted odds ratio 0.86 (95% CI 0.59, 1.24), P ¼ 0.400. The estimated unbiased causal odds ratio for a trial in which everyone adhered to the randomized policy was slightly lower: 0.78 (95% CI 0.49, 1.24) .
Overall, the time to first AAA-related re-intervention was similar between the randomized groups, P ¼ 0.701 (log-rank test) (see Supplementary material online, Figure S2 ) and for the 502 ruptured AAA patients who underwent repair P ¼ 0.674 (log-rank test) ( Figure 3 , Table 1 , details with reasons for re-interventions in Supplementary material online, Table S5 ). Between 31 days and 1 year, there were only 11 patients (4.2%, 12 procedures) with re-interventions in the endovascular group (including 5 endograft related, 1 revision of iliac limb of open repair, 1 limb ischaemia, and 1 colonic ischaemia) and 9 patients (3.7%, 13 procedures) in the open repair group (including 2 for limb ischaemia, 3 colonic ischaemia, 3 for continuing complications of earlier abdominal compartment syndrome, and 1 axillo-bifemoral bypass). Between hospital discharge and 1 year, there was only one AAA-related death, following open repair in the open repair group.
In the endovascular strategy group, 10 patients (3%) were transferred to a secondary hospital vs. 36 patients (12%) in the open repair group: at 30 days, 79 patients (13%) remained in hospital (49/79 in the open repair group). The average times to discharge from hospital (primary and secondary hospitals) were 17 (endovascular strategy group) and 26 days (open repair group), P , 0.001; there was an indication of slightly higher cumulative incidence of discharge in the endovascular strategy group, P ¼ 0.114 ( Figure 4A ). There was strong evidence that a higher proportion of patients from the endovascular strategy group were discharged directly home from the primary hospital, P , 0.001 ( Figure 4B) .
At 3 months, a higher proportion of patients in the endovascular strategy group reported 'no problems' on the physical health dimensions (mobility, self-care, and pain) of the EQ-5D QoL questionnaire, compared to the open repair group (see Supplementary material online, Table S6 ). The resultant EQ-5D mean utility scores were higher in the endovascular strategy vs. the open repair group; the mean differences for ruptured aneurysm AAA survivors were 0.087 (95% CI 0.017, 0.158; P ¼ 0.015) and 0.068 (95% CI 20.004, 0.140; P ¼ 0.063) at 3 and 12 months, respectively ( Table 2 and Supplementary material online, Table S7 ). Average total costs (details in Supplementary material online, Table S8 ), which included the provision of both types of repair at all times, were less in the endovascular strategy (£16 394) vs. the open repair group (£18 723), with a mean incremental cost of -£2329 (95% CI -£5489, £922) ( (Table 2 and Supplementary material online, Table S9 ). When the incremental costs and QALYs are represented on the costeffectiveness plane, most (87%) of the estimates are in the quadrant that designates the endovascular strategy as 'dominant', with lower mean costs and higher mean QALYs ( Figure 5 ). Figures S3 and S5) , including increases in operating theatre staff and varying the costs of the EVAR device from £4000 to £10,000 (vs. £5700 in the base case) or additional interventions, Supplementary material online, Figure S5 . The probability that the Figure 2 (A) Kaplan-Meier estimates by randomized group, across all patients (log-rank test p ¼ 0.325) and (B) 1-year mortality odds ratios for specified subgroups.
Endovascular strategy or open repair endovascular strategy was more cost-effective was .0.90 at all realistic thresholds of willingness to pay for a QALY gain (see Supplementary material online, Figure S4 ).
Discussion
Following repair of a ruptured AAA, it has been proposed that followup, to 90 days and beyond is necessary for patient and clinical decision-making. 9 After 1 year, this trial has shown no significant survival benefit at any time-point for an endovascular strategy (using a standard EVAR device whenever anatomically and operationally possible, with open repair as a default option) vs. open repair. In contrast, there were gains for the endovascular strategy vs. the open repair group with respect to patient-preferred outcomes: faster discharge, more often to home, and QoL and overall the endovascular strategy was cost-effective. Shock with systemic organ damage, rather than type of repair might result in the very high early mortality after ruptured AAA repair and many patients have prolonged hospital stays. There are other potential reasons why there was no difference in survival between the randomized groups. First, the operative mortality from open repair was lower than anticipated. Second, we now know that aortic anatomy, particularly aneurysm neck length, has an important influence on mortality and that those patients who are not candidates for standard EVAR ( 40%) have the highest operative mortality, particularly for open repair, and that those anatomically suitable for EVAR have much lower mortality after either EVAR or open repair. 21 The trial was designed to be inclusive and consider whether the availability of an endovascular service would improve the outcome of all patients with rupture, not just those anatomically suitable for EVAR. So inevitably the endovascular strategy group included a significant proportion of patients who had to be treated with open repair. Therefore, the findings suggesting faster recovery in the endovascular strategy group are notable: shorter overall hospital stay, a greater propensity to be discharged to home, and better early QoL than the open repair group. The between-group mean differences in QoL, 0.087 (3 months) and 0.068 (1 year), exceed the minimum clinically important difference of 0.03, 22 although at 1 year, the mean difference was not statistically significant. The absolute EQ-5 utility scores of the endovascular . 23 In addition, in this trial, there was no evidence of a difference in re-interventions (including those for endoleaks) at any time during the first year after rupture and the risk of re-intervention for endoleak seems lower than the 10-23% range suggested in previous reports: 3, 24, 25 the cost-effectiveness estimates remained robust to sensitivity analyses allowing for additional interventions. This is in contrast to the findings for elective repair, where in the first year AAA-related re-interventions were more common after EVAR and EVAR cost significantly more than open repair. 26 but any missing data were addressed with multiple imputation, which assumes that any systematic differences in outcomes can be explained by the variables included in the imputation model. Thirdly, there was no adjustment for testing of multiple hypotheses (except for subgroup analyses) but all reported outcomes were pre-specified. Fourthly, we did not adhere to the standard American guidelines for the reporting of complications and re-interventions, 27 which are designed primarily for elective surgery. Finally, re-interventions and costs following EVAR for rupture may increase after 1 year and all patients will be followed-up for 3 years to address this. Currently, only the Dutch AJAX trial has reported outcomes to beyond 30 days. There were no between-group differences in health-related QoL and endovascular repair was found not to be cost-effective. 28 There were important distinctions between the IMPROVE and AJAX trials, which makes it difficult to interpret the different conclusions concerning QoL and cost-effectiveness; notably, the AJAX trial included a narrow range of hospitals and patients (recruited over many years and with few women), used aorto-uni-iliac devices (with subsequent femoro-femoral crossover grafting) for endovascular repair and applied unit costs from a single centre. In summary, we present new effectiveness and cost-effectiveness evidence from a large, well-conducted randomized trial, conducted in the challenging circumstance of emergency patients requiring an immediate operation to avoid death. It was based on the randomization of unselected patients, including appropriate representation of women, to optimize the generalizability of the findings and all centres were accredited for providing EVAR in routine and emergency practice. Although the endovascular first strategy offers no survival benefit for patients with ruptured AAA, at up to 1 year, this within-trial report suggests that wider provision of emergency endovascular services is likely to be a cost-effective use of national healthcare systems. The EQ-5D is a QoL measure anchored on a scale that includes 0 (death) and 1 (perfect health).
b
The EQ-5D, QALY, cost, and INB results are reported after multiple imputation to address missing values. The complete case results are shown in the Supplementary material online, Table S7 . The QALY for all randomized patients assumes that for patients without proven rupture, the QoL was the same as at baseline for patients included in EVAR 1 23 (see Supplementary material online, Appendix for further details). 
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